RE: Ava6000 2 data releases coming shortly11 May 2026 07:38
Morning 54retiresoon, I think you may be recalling an answer Chris gave during last September’s interims presentation:
“Great question. Our pre|CISION platform has a couple of key differences compared to these other peptide drug conjugates. We often get asked this by institutional investors.
So let me take Bicycle first. The Bicycle peptide drug conjugates don’t use a cleavable technology. That’s one big difference between the pre|CISION platform and the Bicycle platform. The Bicycle peptide is designed to direct the payload to the tumour. We think the reason pre|CISION and this tumour-specific cleavage is so critical, in our mind, is borne out in the clinic. We see a 10-fold greater concentration of active payload in our biopsy samples compared with the published data from the Bicycle peptide. So while they see 10x concentration, we’re seeing a median 100-fold concentration.
I’ve mentioned this before, but it was really during a board meeting, when I saw those data for the first time, that I thought to myself: I’d really like to have a full-time role. I was just a non-exec at that point.
We also think these data allow us to leverage much more potent payloads. That’s why we can be bold and move into the exatecan programme.”